Nasdaq GlobeNewswire

Medical Marijuana, Inc. Announces $14 Million Debt Reduction and Major Strategic Acquisitions in the Fourth Quarter of 2015

Del

Medical Marijuana, Inc. Eliminates Approximately $14 Million in Long-Term Debt and Extends Maturities on Remaining Debt Obligations and Acquires and Consolidates Into Its Operations 93.4% of HempMeds® Brasil™, Remaining 20% of HempMeds® PX Not Already Owned; 100% Each of HempMeds® Puerto Rico™ and HempMeds® Mexico™

SAN DIEGO, Jan. 13, 2016 (GLOBE NEWSWIRE) -- Medical Marijuana, Inc. (the “Company”) (OTC Pink:MJNA) is pleased to announce the Company has significantly reduced its debt obligation from $24 million at the close of the third quarter (ending 9/30/2015) to approximately $10 million at the close of the fourth quarter (ending 12/31/2015), a reduction of approximately $14 million. The Company also acquired and consolidated several of its partnerships including 93.4% of HempMeds® Brasil™, LLC and the remaining 20% of HempMeds® PX that Medical Marijuana, Inc. did not already own from affiliated parties that comprise the largest shareholder of the Company.

Prior to the acquisitions, the Company sold its RSHO™ products to HempMeds Brasil™ and the other consolidated companies at wholesale, which then in turn sold those products retail to consumers in their respective markets. As a result of the acquisitions, the Company will now realize the full margin between the cost of manufacturing the product and retail pricing on the sales of the product.

The acquisition of the remaining 20% of HempMeds® PX was completed after HempMeds® PX acquired HempMeds® PR (Puerto Rico) Ventures, LLC and KannaMex™, LLC from the same affiliated shareholder. The combined purchase price for the two acquisitions was $13,875,000. Under the terms of the acquisitions, the purchase price is subject to downward adjustment if the aggregate post-acquisition valuation of both entities (as of the transaction date of December 31, 2015) by a recognized independent valuation firm is less than the purchase price and is not subject to upward adjustment unless the aggregate valuation is greater than $100 million (as of December 31, 2015) and such upward valuation is nonetheless subject to a cap of $20 million.

The acquisition by HempMeds® PX of HempMeds® Puerto Rico™ and KannaMex™ was completed immediately prior to the Company’s acquisition of HempMeds® PX for the nominal sum of $100,000. The value of these two entities shall not be included in the aggregate valuations of HempMeds® Brasil™ and HempMeds® PX unless their aggregate valuation is less than the purchase price.

In commenting on the transactions, CEO Stuart Titus stated: “The elimination of $14 million in debt and associated improvement in our balance sheet combined with the acquisitions enhances the Company’s positioning for significant growth. We believe that we’re acquiring 93.4% of HempMeds Brasil™ and the 20% of our flagship U.S.-based operation HempMeds® PX for a fraction of what the independent valuations will show these entities to be worth. In the very unlikely event that we’re wrong, the transaction structure protects the shareholders through a purchase price reduction. I’m most excited by the fact that we’ve completed the acquisitions when Brazil has barely begun to realize what we believe to be the potential for explosive growth. Our products have been approved by the Brazilian government as a prescription by Brazilian doctors to patients suffering from Epilepsy, Parkinson’s and Chronic Pain. These represent enormous markets in Brazil with these conditions estimated to affect approximately 20 million people.”

Titus went on to say, “In addition, HempMeds® Puerto Rico and KannaMex™ were essentially included in the deal for what amounts to mere nominal consideration. Puerto Rico holds great potential, specifically the Company has 12 medical product registrations as well as an agreement for the distribution and marketing of those products by the island’s largest private pharmaceutical sales and distribution company. KannaMex™ made significant inroads in Mexico and we expect to announce some of those accomplishments in the very near future. We believe that Mexico alone has the potential to be as large or even larger than the South American markets we have already been approved in. Our affiliated largest shareholders that entered into these transactions at these prices, and with these protections for the shareholders, have demonstrated an impressive commitment to enhancing shareholder value for itself, and for the other shareholders of the Company. I could not be more optimistic about what this means for our future.”

Summary of above:

Loan Payable Chicago Ventures:

(a) Amount outstanding reduced from $8,299,189 (as of 9/30/2015) to approximately $5.09 million (as of 12/31/2015), a reduction of approximately $3.2 million.

(b) The note still has $2 million in cash, available to be drawn down upon included in the $5.09 million balance.

(c) Extended the maturity date of the note from February 17, 2016, to October 17, 2017.

HDDC Notes Payable:

(a) Reduced HDDC notes payable from $13,980,338 (as of 9/30/15) to approximately $2.96 million of notes payable (as of 12/31/2015), a reduction of approximately $11 million. Extended maturity on the remaining note payable from January 2017 to January 2026.

Below is a summary of the acquisitions and related acquisitions:

(a) The company acquired the 20% balance of HempMeds® PX following HempMeds® PX having acquired 100% of HempMeds® Puerto Rico™ and 100% of HempMeds® Mexico™. As a result the Company now owns 100% of HempMeds® PX and 100% each of HempMeds® Puerto Rico™ and HempMeds® Mexico™ by virtue of its ownership of HempMeds® PX. The Company acquired 93.4 percent of HempMeds® Brasil™.

About Medical Marijuana Inc.
The mission of Medical Marijuana, Inc. (OTC Pink:MJNA) is to be the premier hemp industry innovator, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value.

For more information, please visit the company's website at: www.MedicalMarijuanaInc.com.

About HempMeds® Brasil
HempMeds Brasil™ currently has three cannabis products approved for importation into Brazil as a prescription medication for Epilepsy, Parkinson's and Chronic Pain. The company had the first-ever cannabis product allowed for import into Brazil and its products are currently subsidized by the Brazilian government, under their health care system, for all three medical indications listed above. HempMeds Brasil™ is working on additional approvals for multiple indications.

For more information, please the company’s website at: www.HempMeds.com.br.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.

FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.

LEGAL DISCLOSURE
Medical Marijuana Inc. and HempMeds do not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.

         For further information, please contact:
         
         Public Relations contact:
         Andrew Hard
         Chief Executive Officer
         CMW Media
         P. 888-829-0070
         andrew.hard@cmwmedia.com
         www.cmwmedia.com
         
         Corporate Contact:
         Medical Marijuana, Inc.
         Toll Free: 888-OTC-MJNA (888-682-6562)
         www.medicalmarijuanainc.com
         www.facebook.com/mjnainc

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

GlobeNewswire Test Release26.5.2018 07:00Pressemelding

LOS ANGELES, May 25, 2018 (GLOBE NEWSWIRE) -- This is a test from GlobeNewswire. Readers are advised to disregard. TESTING -- TESTING -- TESTING -- TESTING -- TESTING -- TESTING -- TESTING -- TESTING – -END- CONTACT: Karen Yu Director, GlobeNewswire Product Management Direct: +1 310 258 6917 Mobile: +1 626 389 7427 or Magali Rolandez Senior Manager, Media Relations/Content Distribution Europe Direct: +44 (0) 203 753 2215 Mobile: +44 (0) 7785 619 539

Medibio Corporate Health Extends Global Footprint Signing Contract with Jacobs Engineering25.5.2018 16:38Pressemelding

Jacobs, one of the world's largest engineering and environmental consultancy groups, has more than 70,000 employees globally SYDNEY, Australia and MINNEAPOLIS, May 25, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company) (ASX:MEB) (OTCQB:MDBIF), a mental health technology company, today announced a significant contract for Medibio's Corporate Health product with Dallas, TX-based Jacobs Engineering across their Asia Pacific, Middle East, and European divisions. Through the Mental Health Check-In, companies can offer employees an end-to-end mental health program, direct to their devices, to see how the mind and body are tracking. It's a personalized, private, and objective way to see the unseeable: mental health issues in the workplace. Employees are provided the opportunity to confidentially check-in on their mental health and receive personalized confidential results from both an objective biometric screening in conjunction with a 12-minute subjective survey. Employers receive

VIRGIN PULSE ANNOUNCES INDUSTRY-LEADING GDPR COMPLIANCE25.5.2018 14:00Pressemelding

Virgin Pulse Extends the GDPR's Strong Data Privacy Rights to All Clients and Members Across the Globe PROVIDENCE, R.I., May 25, 2018 (GLOBE NEWSWIRE) -- Virgin Pulse, the leading global provider of digital employee health, wellbeing and engagement solutions, today announced that it has achieved compliance with the EU General Data Protection Regulation (GDPR) for the Virgin Pulse platform. The company has also appointed Associate Counsel Beatrice Botti as Data Protection Officer (DPO) to oversee the Virgin Pulse privacy program. With this achievement, Virgin Pulse leads the market as the first company in the wellbeing and engagement industry to fully meet the comprehensive standards of the new GDPR data privacy law. The company has completed a thorough review of its internal data collection, storage and handling processes and implemented enhancements to achieve GDPR compliance and give all Virgin Pulse customers and members greater control over their personal data. The GDPR is the firs

Resverlogix Provides Unrestricted Educational Grant for Epigenetic Symposium at International Renal Congress25.5.2018 07:45Pressemelding

CALGARY, Alberta, May 24, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that on Friday, May 25, 2018, at the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress in Copenhagen, Denmark, the Company is supporting a symposium titled: "Epigenetics in CKD & CVD: A potential breakthrough therapy?" The symposium highlights the role of epigenetics and BET-inhibition in chronic kidney disease and cardiovascular disease, especially in patients with diabetes mellitus, and the significant unmet need that still exists in this patient population. The symposium is co-chaired by Vincent M. Brandenburg, MD - Nephrologist, Aachen, Germany and Kamyar Kalantar-Zadeh, MD - UC Irvine School of Medicine, Irvine, CA, USA, both leading scientists also serving as advisors to Resverlogix's Renal program. The speakers and agenda are as follows: Introduction Vincent M. Brandenburg, MD - University Hospital of the RWTH

Atico Reports Consolidated Financial Results for the First Quarter of 201824.5.2018 22:30Pressemelding

(All amounts expressed in US dollars, unless otherwise stated) VANCOUVER, British Columbia, May 24, 2018 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the "Company" or "Atico") (TSX.V:ATY) (OTC:ATCMF) today announced its financial results for the three months ended March 31, 2018, posting a net income of $0.4 million. Fernando E. Ganoza, CEO and Director, commented, "The strong production and all-in sustaining cash cost of $1.85 achieved this quarter is not reflected in the financial results as a large concentrate shipment was delayed to the second quarter, along with the revenue associated with those tonnes. The shipping schedule is expected to stabilize during the second quarter, where we will then benefit from the additional shipped concentrate and recognized revenue. We anticipate strong financial results in the next quarter." Mr. Ganoza continued, "Our emphasis will continue to be on further strengthening our balance sheet, improving production costs and most importantly regional

Luxembourg Announced as SNOMED International's Newest Member24.5.2018 15:16Pressemelding

London, United Kingdom, May 24, 2018 (GLOBE NEWSWIRE) -- SNOMED International and Agence eSanté Luxembourg are pleased to announce that Luxembourg has joined the organization as its thirty-second Member. Luxembourg, one of the leading nations in the area of information and communication technology, has set the development of eHealth technologies as a high priority. Agence eSanté, Luxembourg's national agency for the exchange and sharing of medical data, has set an overall mission to facilitate clinical information exchange both within Luxembourg and across other international actors. To work towards this reality, the agency has taken part in discussions about standardization across Europe, a contributing building block achieved with its membership in SNOMED International. With their membership, Agence eSanté has committed their support for the use of structured clinical terminology. When applied to the health sector, interoperability ensures that information systems, and through them h

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom